Neuland Laboratories Receives US FDA EIR for Unit 3 Manufacturing Facility
Neuland Laboratories Ltd 路 Others (Uncategorized) 路 15 Oct 2026, 3:13 am
Neuland Laboratories Receives US FDA EIR for Unit 3 Manufacturing Facility Neuland Laboratories has received an Establishment Inspection Report (EIR) from the US FDA for its Unit 3 manufacturing facility located at Gaddapotharam Village, Sangareddy District. The inspection, conducted between 10th Aug'26 and 14th Aug'26, has been formally concluded as "closed" by the US FDA, clearing regulatory overhang for the manufacturing site.
Original exchange filing (PDF)
More announcements from Neuland Laboratories Ltd
- Intimation about Schedule of Analyst / Institutional Investor Meeting on November 17, 2026 路 06 Nov 2026
- Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA) 路 05 Nov 2026
- Audio Recording of the Earnings call conducted on November 3, 2026 路 04 Nov 2026
- Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Press Release on the Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Disclosure under Regulation 30 of SEBI Listing Regulations 路 03 Nov 2026
- Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 03 Nov 2026
